Medincell SA
PAR:MEDCL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Medincell SA
Interest Expense
Medincell SA
Interest Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Medincell SA
PAR:MEDCL
|
Interest Expense
€5.3m
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Sanofi SA
PAR:SAN
|
Interest Expense
€509m
|
CAGR 3-Years
9%
|
CAGR 5-Years
2%
|
CAGR 10-Years
2%
|
|
|
Ipsen SA
PAR:IPN
|
Interest Expense
€36.1m
|
CAGR 3-Years
15%
|
CAGR 5-Years
6%
|
CAGR 10-Years
39%
|
|
|
Vetoquinol SA
PAR:VETO
|
Interest Expense
€995k
|
CAGR 3-Years
18%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Virbac SA
PAR:VIRP
|
Interest Expense
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Boiron SA
PAR:BOI
|
Interest Expense
€999k
|
CAGR 3-Years
41%
|
CAGR 5-Years
21%
|
CAGR 10-Years
-3%
|
|
Medincell SA
Glance View
MedinCell SA is a pharmaceutical company, which engages in the development of injectable products in therapeutic areas. The company is headquartered in Jacou, Occitanie and currently employs 150 full-time employees. The company went IPO on 2018-10-08. The firm is focused on the development of therapeutic solutions with worldwide access. The firm works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.
See Also
What is Medincell SA's Interest Expense?
Interest Expense
5.3m
EUR
Based on the financial report for Sep 30, 2025, Medincell SA's Interest Expense amounts to 5.3m EUR.
What is Medincell SA's Interest Expense growth rate?
Interest Expense CAGR 5Y
8%
Over the last year, the Interest Expense growth was 12%. The average annual Interest Expense growth rates for Medincell SA have been 6% over the past three years , 8% over the past five years .
